Stryker Past Earnings Performance
Past criteria checks 5/6
Stryker has been growing earnings at an average annual rate of 11.3%, while the Medical Equipment industry saw earnings growing at 18.2% annually. Revenues have been growing at an average rate of 9.5% per year. Stryker's return on equity is 15.5%, and it has net margins of 14.4%.
Key information
11.33%
Earnings growth rate
11.00%
EPS growth rate
| Medical Equipment Industry Growth | 8.90% |
| Revenue growth rate | 9.54% |
| Return on equity | 15.55% |
| Net Margin | 14.43% |
| Last Earnings Update | 30 Jun 2026 |
Recent past performance updates
Recent updates
New Narrative • Sep 03
Stryker — Defensive Compounder Riding Demographics + Mako
Stryker is my defensive-growth anchor: a high-quality medtech leader in orthopaedics, surgical equipment and MedSurg, riding the durable tailwind of an ageing population. Demographics, not hype, drive this thesis.Seeking Alpha • Aug 18
Stryker Corporation: Hold For Quality, Wait For The Dip
Summary Stryker is a MedTech compounder with 11% organic revenue growth and expanding margins, driven by technology leadership and a razor/razorblade model. SYK's wide economic moat is underpinned by high switching costs, clinical evidence, patents, and scale advantages in logistics. I value SYK at $336.24 per share, near its current price of $341, offering no margin of safety; recommend holding for current shareholders. Prospective investors should watch for a 15% discount to fair value, with an attractive entry at $289 per share. Read the full article on Seeking Alpha
Narrative Update • Jun 14
SYK: Hospital Digitization And Cyber Resilience Will Support 2026 Recovery Prospects
Stryker's fair value estimate has been adjusted slightly lower to $386.80 from $389.24 as analysts temper price targets in response to lower utilization expectations, inflation headwinds, and more conservative long term margin and P/E assumptions. Analyst Commentary Recent Street research on Stryker has been active, with most updates focused on resetting price targets and reassessing long term assumptions around utilization, inflation, and margins.Narrative Update • May 31
SYK: Hospital Digitization And Cyber Resilience Will Drive 2026 Rebound Potential
Analysts have trimmed Stryker's updated price target slightly, reflecting a minor change of about $0.11 and combining a series of recent target cuts from multiple firms with one modest increase, as they reassess assumptions around discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts who recently raised or affirmed higher targets highlight what they see as healthy fundamentals in U.S. medical technology, which they argue can support Stryker's growth assumptions that underpin current P/E expectations.Narrative Update • May 14
SYK: Hospital Digitization And Cyber Resilience Will Support 2026 Upside
Analysts have nudged Stryker's fair value estimate lower to about $389 from roughly $419, as a wave of reduced price targets led by firms like Truist, Barclays and others has been paired with updated assumptions for slightly lower future P/E multiples, alongside higher projected revenue growth and profit margins. Analyst Commentary Recent research around Stryker has tilted more cautious, with a cluster of reduced price targets across multiple firms, offset by a smaller group of more supportive views.Analysis Article • May 04
Stryker Corporation Just Missed Earnings - But Analysts Have Updated Their Models
As you might know, Stryker Corporation ( NYSE:SYK ) last week released its latest first-quarter, and things did not...Narrative Update • Apr 21
SYK: Diversified Portfolio And Hospital Digitization Will Support 2026 Upside
Analysts have trimmed Stryker's fair value estimate by about $6 to $419, reflecting slightly higher discount rate assumptions, a modestly lower revenue growth outlook, and a slightly lower future P/E multiple, even as profit margin expectations are marginally higher. Analyst Commentary Recent Street research on Stryker shows a mix of optimism about the company’s long term growth drivers and caution around near term valuation and risk.Narrative Update • Apr 06
SYK: Diversified Growth Drivers And Robotics Adoption Will Support 2026 Upside
The updated analyst price target for Stryker edges slightly higher to about $425 per share, as analysts balance recent target trims with continued support from firms highlighting a healthy U.S. medtech backdrop, diversified growth drivers, and potential near term catalysts. Analyst Commentary Recent research paints a mixed but generally constructive picture for Stryker, with several firms adjusting price targets and ratings as they reassess growth drivers, execution, and valuation against a still supportive U.S. medtech backdrop.Narrative Update • Mar 22
SYK: Diversified Portfolio And Robotics Adoption Will Support 2026 Upside
Analysts have trimmed the Stryker fair value estimate by less than $1 to about $424 per share, reflecting a slightly higher discount rate and a modestly lower assumed future P/E multiple. Recent research cites mixed price target moves and differing views on near term catalysts and sector trends.Narrative Update • Mar 07
SYK: Diversified Product Reach And Robotics Expansion Will Support 2026 Upside
The analyst fair value estimate for Stryker has edged up by about $0.50 to $424.90, as analysts factor in recent price target moves, including several Outperform ratings that highlight the company's broader product reach and diversified growth profile. Analyst Commentary Recent research on Stryker reflects a mix of optimism about the company’s growth profile and some caution on valuation and sector level risks.Narrative Update • Feb 20
SYK: Diversified Medtech Portfolio And Robotics Execution Will Support 2026 Upside
Analysts made a modest trim to their blended Stryker price target, reflecting mixed recent revisions that range from higher targets up to $465 with Outperform ratings to lower targets near $390 and $399 with a Hold rating, as they weigh the company's broader product reach and expected sales and earnings trends against valuation and sector-level risks. Analyst Commentary Recent research on Stryker reflects a split view, with some analysts leaning into the growth story and others more guarded on valuation and sector risks.Analysis Article • Feb 09
Stryker's (NYSE:SYK) Earnings Seem To Be Promising
Stryker Corporation's ( NYSE:SYK ) recent earnings report didn't offer any surprises, with the shares unchanged over...Analysis Article • Feb 07
Stryker (NYSE:SYK) Is Due To Pay A Dividend Of $0.88
Stryker Corporation ( NYSE:SYK ) will pay a dividend of $0.88 on the 30th of April. This takes the annual payment to...Narrative Update • Feb 06
SYK: Orthopedics And Robotics Execution Will Support 2026 Rebound In Medtech Sentiment
Analysts have reduced their fair value estimate for Stryker by about $3 to $424, reflecting slightly softer revenue growth assumptions, a future P/E multiple closer to 34, and a modestly higher profit margin outlook following recent mixed price target changes across Wall Street. Analyst Commentary Recent research coverage on Stryker reflects a mix of optimism and caution, with several firms adjusting price targets and ratings in different directions.Narrative Update • Jan 22
SYK: Orthopedics And Robotics Execution Will Support 2026 Upside Potential
Analysts have inched their average price target on Stryker higher, with a modest fair value lift to about US$427.40, as they weigh mixed target changes across firms against ongoing views that the company remains a high quality large-cap MedTech name heading into 2026. Analyst Commentary Recent Street research on Stryker shows a split tape, with several firms lifting targets and ratings while others trim fair values or stay neutral.Narrative Update • Jan 08
SYK: Orthopedics Strength And Robotics Adoption Will Support Long-Term Upside
Narrative Update: Stryker The analyst price target for Stryker has been adjusted slightly lower to reflect a fair value estimate of about $427.22. Analysts point to mixed but generally solid recent research that highlights compressed forward multiples, updated targets in the $390 to $453 range, and ongoing views of Stryker as a high quality large cap MedTech name, with attractive entry points and healthy procedure and CapEx trends into 2026.Narrative Update • Dec 19
SYK: Expanding Orthopedics And Robotics Footprint Will Drive Long-Term Upside Potential
Analysts have modestly trimmed our fair value estimate for Stryker to approximately $428 from about $433 per share, reflecting a slightly higher discount rate and lower valuation multiple, even as they acknowledge improving revenue growth, rising profit margins, and continued operating leverage highlighted in recent research updates and investor day commentary. Analyst Commentary Street research on Stryker has been active in recent weeks, with modestly higher and lower price targets reflecting a balanced mix of optimism on execution and caution on MedTech sentiment and relative growth.Analysis Article • Dec 14
Stryker (NYSE:SYK) Has Announced That It Will Be Increasing Its Dividend To $0.88
Stryker Corporation's ( NYSE:SYK ) periodic dividend will be increasing on the 30th of January to $0.88, with investors...Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How Stryker makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 26 | 25,837 | 3,729 | 8,423 | 1,635 |
| 31 Mar 26 | 25,270 | 3,337 | 8,298 | 1,609 |
| 31 Dec 25 | 25,116 | 3,246 | 8,244 | 1,604 |
| 30 Sep 25 | 24,381 | 2,943 | 8,138 | 1,571 |
| 30 Jun 25 | 23,818 | 2,918 | 7,974 | 1,539 |
| 31 Mar 25 | 23,218 | 2,859 | 7,771 | 1,499 |
| 31 Dec 24 | 22,595 | 2,993 | 7,503 | 1,463 |
| 30 Sep 24 | 21,974 | 3,590 | 7,345 | 1,457 |
| 30 Jun 24 | 21,389 | 3,448 | 7,224 | 1,433 |
| 31 Mar 24 | 20,963 | 3,361 | 7,069 | 1,416 |
| 31 Dec 23 | 20,498 | 3,165 | 6,961 | 1,387 |
| 30 Sep 23 | 19,885 | 2,585 | 6,690 | 1,364 |
| 30 Jun 23 | 19,455 | 2,709 | 6,494 | 1,367 |
| 31 Mar 23 | 18,952 | 2,627 | 6,278 | 1,372 |
| 31 Dec 22 | 18,449 | 2,358 | 6,099 | 1,367 |
| 30 Sep 22 | 17,948 | 2,457 | 6,014 | 1,372 |
| 30 Jun 22 | 17,629 | 2,079 | 5,925 | 1,322 |
| 31 Mar 22 | 17,430 | 2,015 | 5,929 | 1,281 |
| 31 Dec 21 | 17,108 | 1,994 | 5,752 | 1,235 |
| 30 Sep 21 | 16,669 | 1,900 | 5,525 | 1,159 |
| 30 Jun 21 | 16,246 | 2,083 | 5,297 | 1,095 |
| 31 Mar 21 | 14,716 | 1,408 | 4,900 | 1,018 |
| 31 Dec 20 | 14,351 | 1,599 | 4,768 | 984 |
| 30 Sep 20 | 14,220 | 1,756 | 4,766 | 983 |
| 30 Jun 20 | 14,070 | 1,601 | 4,824 | 987 |
| 31 Mar 20 | 14,956 | 2,164 | 4,995 | 1,000 |
| 31 Dec 19 | 14,884 | 2,083 | 4,968 | 971 |
| 30 Sep 19 | 14,549 | 3,426 | 4,970 | 938 |
| 30 Jun 19 | 14,204 | 3,550 | 4,914 | 913 |
| 31 Mar 19 | 13,876 | 3,522 | 4,864 | 883 |
| 31 Dec 18 | 13,601 | 3,553 | 4,808 | 862 |
| 30 Sep 18 | 13,276 | 1,236 | 4,687 | 846 |
| 30 Jun 18 | 13,040 | 1,080 | 4,556 | 823 |
| 31 Mar 18 | 12,730 | 1,019 | 4,484 | 799 |
| 31 Dec 17 | 12,444 | 1,020 | 4,380 | 787 |
| 30 Sep 17 | 12,130 | 1,779 | 4,239 | 771 |
| 30 Jun 17 | 11,957 | 1,700 | 4,167 | 757 |
| 31 Mar 17 | 11,785 | 1,689 | 4,076 | 748 |
| 31 Dec 16 | 11,325 | 1,647 | 3,941 | 715 |
| 30 Sep 16 | 10,883 | 1,659 | 3,828 | 690 |
| 30 Jun 16 | 10,470 | 1,605 | 3,703 | 661 |
| 31 Mar 16 | 10,062 | 1,617 | 3,591 | 632 |
| 31 Dec 15 | 9,946 | 1,439 | 3,511 | 625 |
| 30 Sep 15 | 9,849 | 1,177 | 3,445 | 614 |
Quality Earnings: SYK has high quality earnings.
Growing Profit Margin: SYK's current net profit margins (14.4%) are higher than last year (12.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SYK's earnings have grown by 11.3% per year over the past 5 years.
Accelerating Growth: SYK's earnings growth over the past year (27.8%) exceeds its 5-year average (11.3% per year).
Earnings vs Industry: SYK earnings growth over the past year (27.8%) exceeded the Medical Equipment industry 15.6%.
Return on Equity
High ROE: SYK's Return on Equity (15.5%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/09 04:11 |
| End of Day Share Price | 2026/09/09 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Stryker Corporation is covered by 50 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Jeffrey Johnson | Baird |
| Adam Feinstein | Barclays |